Pharmaceuticals Company Announces Promising Results For FAP Treatment

Biodexa Pharmaceuticals (NASDAQ:BDRX) has recently announced promising phase 2 results for its newly in-licensed drug, eRapa, aimed at treating familial adenomatous polyposis (FAP). FAP is a primarily genetic disease of the lower gastrointestinal (GI) tract for which there is currently no remedy except surgical removal of the colon and/or rectum. With a clinical trial involving 30 adult patients, three groups received the same dose of the drug but with different regimens over 12 months. The results have brought hope to FAP patients who otherwise face a 100% lifetime risk of colorectal cancer. This article delves into the details of the trial, the significance of these findings, and what the future holds for eRapa and FAP patients. $Biodexa Pharmaceuticals(BDRX.US)$